Clinical Trial Update: Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients [Phase 2]

View source ↗

Summary

This update summarizes the completed Phase 2 trial of dabrafenib and trametinib in malignant melanoma patients who were pretreated with BRAF inhibitors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• MEKINIST (trametinib)
• TAFINLAR (DABRAFENIB)

Snippet

Sponsor: Universitair Ziekenhuis Brussel | Conditions: Malignant Melanoma | Phase 2 | Status: COMPLETED